Chavez, J., Westin, J., Muñoz, J., Bachy, E., Jørgensen, J., Perini, G., Morillo, D., Costa, A., Rao, P., Moucheron, B. D., Yang, G., Carrancio, S., Sudhindra, A., Pourdehnad, M., Voetsch, J., Perna, S., Michot, J. (2025). Golcadomide (GOLCA), a potential, first-in-class, oral CELMoD™ agent, ± rituximab (R) in patients with Relapsed/Refractory follicular lymphoma (R/R FL): Phase 1/2 study extended follow-up Results. Blood. https://doi.org/10.1182/blood-2025-1006